| Outcome |
Relative effect 95%CI |
LoD |
Trt. better when |
|
I2 |
k (RCT/OBS)
|
Bayesian probability
|
Overall ROB
|
Publication bias |
Degree of certainty |
Endpoint importance |
Published MA |
efficacy endpoints 00 |
| deaths (OS) | 0.75 [0.66, 0.85] | | < 1 | | 3% | 5 studies (5/-) | 100.0 % | some concern | not evaluable | moderate | crucial | - |
| deaths (OS) (extension) | 0.68 [0.57, 0.81] | | < 1 | | 0% | 2 studies (2/-) | 100.0 % | some concern | not evaluable | moderate | important | - |
| MFS | 0.53 [0.37, 0.76] | | < 1 | | 0% | 1 study (1/-) | 100.0 % | NA | not evaluable | | important | - |
| PFS (extension) | 0.61 [0.53, 0.70] | | < 1 | | 0% | 2 studies (2/-) | 100.0 % | some concern | not evaluable | moderate | important | - |
| progression or deaths (PFS) | 0.60 [0.51, 0.71] | | < 1 | | 60% | 5 studies (5/-) | 100.0 % | some concern | not evaluable | moderate | important | - |
| RFS (extension) | 0.59 [0.49, 0.71] | | < 1 | | 0% | 1 study (1/-) | 100.0 % | NA | not evaluable | | important | - |
| RFS/DFS | 0.57 [0.43, 0.75] | | < 1 | | 0% | 1 study (1/-) | 100.0 % | NA | not evaluable | | important | - |
| DMFS | 0.60 [0.49, 0.73] | | < 1 | | 0% | 1 study (1/-) | 100.0 % | NA | not evaluable | | non important | - |
| objective responses (ORR) | 3.69 [2.00, 6.80] | | > 1 | | 85% | 5 studies (5/-) | 100.0 % | some concern | not evaluable | moderate | non important | - |
safety endpoints 00 |
| AE (any grade) | 0.35 [0.02, 7.12] | | < 1 | | 94% | 2 studies (2/-) | 74.9 % | low | not evaluable | high | non important | - |
| AE (grade 3-4) | 0.71 [0.09, 5.61] | | < 1 | | 99% | 2 studies (2/-) | 62.5 % | low | not evaluable | high | non important | - |
| STRAE (any grade) | 0.65 [0.46, 0.92] | | < 1 | | 0% | 2 studies (2/-) | 99.3 % | some concern | not evaluable | moderate | non important | - |
| STRAE (grade 3-4) | 0.92 [0.06, 14.79] | | < 1 | | 0% | 2 studies (2/-) | 52.3 % | some concern | not evaluable | moderate | non important | - |
| TRAE (any grade) | 1.11 [0.73, 1.69] | | < 1 | | 81% | 5 studies (5/-) | 31.9 % | some concern | serious | moderate | non important | - |
| TRAE (grade 3-4) | 0.95 [0.44, 2.06] | | < 1 | | 92% | 5 studies (5/-) | 54.7 % | some concern | not evaluable | moderate | non important | - |
| TRAE leading to death (grade 5) | 1.51 [0.30, 7.49] | | < 1 | | 0% | 5 studies (5/-) | 30.8 % | some concern | serious | moderate | non important | - |
| TRAE leading to discontinuation (any grade) | 1.05 [0.74, 1.50] | | < 1 | | 0% | 4 studies (4/-) | 39.0 % | some concern | not evaluable | moderate | non important | - |
| TRAE leading to discontinuation (grade 3-4) | 1.92 [0.84, 4.37] | | < 1 | | 0% | 4 studies (4/-) | 6.1 % | some concern | not evaluable | moderate | non important | - |
TRAE (grade 3-4) endpoints 00 |
| Abdominal pain TRAE (grade 3-4) | 0.92 [0.06, 14.79] | | < 1 | | 0% | 2 studies (2/-) | 52.3 % | some concern | not evaluable | moderate | non important | - |
| Adrenal insufficiency TRAE (grade 3-4) | 1.97 [0.07, 58.99] | | < 1 | | 0% | 1 study (1/-) | 34.9 % | NA | not evaluable | | non important | - |
| Alopecia TRAE (grade 3-4) | 0.94 [0.13, 6.69] | | < 1 | | 0% | 4 studies (4/-) | 52.5 % | some concern | not evaluable | moderate | non important | - |
| Anaemia TRAE (grade 3-4) | 0.25 [0.05, 1.30] | | < 1 | | 36% | 4 studies (4/-) | 95.0 % | some concern | not evaluable | moderate | non important | - |
| Arthralgia TRAE (grade 3-4) | 1.42 [0.35, 5.86] | | < 1 | | 0% | 5 studies (5/-) | 31.2 % | some concern | not evaluable | moderate | non important | - |
| Asthenia TRAE (grade 3-4) | 0.57 [0.15, 2.25] | | < 1 | | 0% | 4 studies (4/-) | 78.8 % | some concern | not evaluable | moderate | non important | - |
| Chills TRAE (grade 3-4) | 0.92 [0.06, 14.79] | | < 1 | | 0% | 2 studies (2/-) | 52.3 % | some concern | not evaluable | moderate | non important | - |
| Colitis TRAE (grade 3-4) | 0.81 [0.21, 3.18] | | < 1 | | 71% | 5 studies (5/-) | 61.6 % | some concern | not evaluable | moderate | non important | - |
| Constipation TRAE (grade 3-4) | 0.94 [0.13, 6.69] | | < 1 | | 0% | 4 studies (4/-) | 52.5 % | some concern | not evaluable | moderate | non important | - |
| Cough TRAE (grade 3-4) | 0.92 [0.06, 14.79] | | < 1 | | 0% | 2 studies (2/-) | 52.3 % | some concern | not evaluable | moderate | non important | - |
| Decreased appetite TRAE (grade 3-4) | 0.94 [0.13, 6.69] | | < 1 | | 0% | 4 studies (4/-) | 52.5 % | some concern | not evaluable | moderate | non important | - |
| Diabetes TRAE (grade 3-4) | 4.89 [0.54, 44.56] | | < 1 | | 0% | 2 studies (2/-) | 8.1 % | low | not evaluable | high | non important | - |
| Diarrhoea TRAE (grade 3-4) | 0.79 [0.42, 1.51] | | < 1 | | 0% | 5 studies (5/-) | 75.9 % | some concern | not evaluable | moderate | non important | - |
| Dry skin TRAE (grade 3-4) | 0.94 [0.13, 6.69] | | < 1 | | 0% | 4 studies (4/-) | 52.5 % | some concern | not evaluable | moderate | non important | - |
| Dyspnoea TRAE (grade 3-4) | 0.94 [0.15, 5.79] | | < 1 | | 0% | 3 studies (3/-) | 52.6 % | some concern | not evaluable | moderate | non important | - |
| Endocrine disorders TRAE (grade 3-4) | 18.05 [1.04, 312.27] | | < 1 | | 0% | 1 study (1/-) | 2.4 % | NA | not evaluable | | non important | - |
| Fatigue TRAE (grade 3-4) | 0.35 [0.15, 0.82] | | < 1 | | 0% | 4 studies (4/-) | 99.2 % | some concern | not evaluable | moderate | non important | - |
| Gastrointestinal disorders TRAE (grade 3-4) | 5.01 [1.09, 22.98] | | < 1 | | 0% | 1 study (1/-) | 1.9 % | NA | not evaluable | | non important | - |
| Headache TRAE (grade 3-4) | 0.92 [0.06, 14.79] | | < 1 | | 0% | 2 studies (2/-) | 52.3 % | some concern | not evaluable | moderate | non important | - |
| Hepatitis TRAE (grade 3-4) | 3.97 [1.30, 12.10] | | < 1 | | 0% | 5 studies (5/-) | 0.8 % | some concern | not evaluable | moderate | non important | - |
| Hyperthyroidism TRAE (grade 3-4) | 0.81 [0.16, 4.03] | | < 1 | | 0% | 5 studies (5/-) | 60.0 % | some concern | not evaluable | moderate | non important | - |
| Hypophysitis TRAE (grade 3-4) | 0.94 [0.24, 3.66] | | < 1 | | 0% | 5 studies (5/-) | 53.7 % | some concern | not evaluable | moderate | non important | - |
| Hypothyroidism TRAE (grade 3-4) | 1.13 [0.21, 6.16] | | < 1 | | 0% | 5 studies (5/-) | 44.5 % | some concern | serious | moderate | non important | - |
| Increase AST TRAE (grade 3-4) | 0.35 [0.05, 2.37] | | < 1 | | 0% | 2 studies (2/-) | 85.7 % | some concern | not evaluable | moderate | non important | - |
| Increased ALT TRAE (grade 3-4) | 0.35 [0.05, 2.37] | | < 1 | | 0% | 2 studies (2/-) | 85.7 % | some concern | not evaluable | moderate | non important | - |
| Leucopenia TRAE (grade 3-4) | 0.07 [0.01, 0.50] | | < 1 | | 0% | 2 studies (2/-) | 99.5 % | some concern | not evaluable | moderate | non important | - |
| Maculopapular rash TRAE (grade 3-4) | 1.09 [0.22, 5.44] | | < 1 | | 0% | 4 studies (4/-) | 45.6 % | some concern | not evaluable | moderate | non important | - |
| Myalgia TRAE (grade 3-4) | 0.94 [0.22, 4.02] | | < 1 | | 0% | 4 studies (4/-) | 53.2 % | some concern | not evaluable | moderate | non important | - |
| Myocarditis TRAE (grade 3-4) | 1.97 [0.07, 58.99] | | < 1 | | 0% | 1 study (1/-) | 34.9 % | NA | not evaluable | | non important | - |
| Myositis TRAE (grade 3-4) | 0.94 [0.10, 9.08] | | < 1 | | 0% | 3 studies (3/-) | 52.0 % | some concern | not evaluable | moderate | non important | - |
| Nausea TRAE (grade 3-4) | 0.34 [0.08, 1.37] | | < 1 | | 0% | 5 studies (5/-) | 93.5 % | some concern | not evaluable | moderate | non important | - |
| Nephritis TRAE (grade 3-4) | 1.03 [0.15, 6.90] | | < 1 | | 0% | 3 studies (3/-) | 48.7 % | some concern | not evaluable | moderate | non important | - |
| Neutropenia TRAE (grade 3-4) | 0.18 [0.04, 0.96] | | < 1 | | 0% | 4 studies (4/-) | 97.7 % | some concern | not evaluable | moderate | non important | - |
| Pancreatitis TRAE (grade 3-4) | 1.20 [0.18, 7.92] | | < 1 | | 0% | 3 studies (3/-) | 42.4 % | some concern | not evaluable | moderate | non important | - |
| Paraesthesia TRAE (grade 3-4) | 0.63 [0.10, 3.88] | | < 1 | | 0% | 4 studies (4/-) | 69.0 % | some concern | not evaluable | moderate | non important | - |
| Peripheral neuropathy TRAE (grade 3-4) | 0.24 [0.03, 2.13] | | < 1 | | 0% | 2 studies (2/-) | 89.9 % | some concern | not evaluable | moderate | non important | - |
| Pneumonitis TRAE (grade 3-4) | 2.19 [0.55, 8.64] | | < 1 | | 0% | 5 studies (5/-) | 13.3 % | some concern | not evaluable | moderate | non important | - |
| Pruritic rash TRAE (grade 3-4) | 0.92 [0.06, 14.79] | | < 1 | | 0% | 2 studies (2/-) | 52.3 % | some concern | not evaluable | moderate | non important | - |
| Pruritus TRAE (grade 3-4) | 0.95 [0.16, 5.49] | | < 1 | | 0% | 5 studies (5/-) | 52.3 % | some concern | not evaluable | moderate | non important | - |
| Pyrexia TRAE (grade 3-4) | 0.92 [0.06, 14.79] | | < 1 | | 0% | 2 studies (2/-) | 52.3 % | some concern | not evaluable | moderate | non important | - |
| Rash TRAE (grade 3-4) | 1.13 [0.21, 6.19] | | < 1 | | 0% | 5 studies (5/-) | 44.3 % | some concern | serious | moderate | non important | - |
| Respiratory, thoracic and mediastinal disorders TRAE (grade 3-4) | 7.94 [0.42, 150.67] | | < 1 | | 0% | 1 study (1/-) | 8.6 % | NA | not evaluable | | non important | - |
| Sarcoidosis TRAE (grade 3-4) | 0.99 [0.02, 49.80] | | < 1 | | 0% | 1 study (1/-) | 50.3 % | NA | not evaluable | | non important | - |
| Severe skin reaction TRAE (grade 3-4) | 5.95 [0.30, 119.02] | | < 1 | | 0% | 1 study (1/-) | 12.5 % | NA | not evaluable | | non important | - |
| Skin and subcutaneous tissue disorders TRAE (grade 3-4) | 1.97 [0.07, 58.99] | | < 1 | | 0% | 1 study (1/-) | 34.9 % | NA | not evaluable | | non important | - |
| Thrombocytopenia TRAE (grade 3-4) | 0.18 [0.03, 1.07] | | < 1 | | 0% | 2 studies (2/-) | 97.0 % | some concern | not evaluable | moderate | non important | - |
| Thyroiditis TRAE (grade 3-4) | 0.99 [0.02, 49.80] | | < 1 | | 0% | 1 study (1/-) | 50.3 % | NA | not evaluable | | non important | - |
| Uveitis TRAE (grade 3-4) | 1.13 [0.21, 6.18] | | < 1 | | 0% | 5 studies (5/-) | 44.4 % | some concern | serious | moderate | non important | - |
| Vitiligo TRAE (grade 3-4) | 0.97 [0.10, 9.32] | | < 1 | | 0% | 3 studies (3/-) | 51.1 % | some concern | not evaluable | moderate | non important | - |
| Vomiting TRAE (grade 3-4) | 0.38 [0.10, 1.43] | | < 1 | | 0% | 4 studies (4/-) | 92.4 % | some concern | not evaluable | moderate | non important | - |
| Weight decreased TRAE (grade 3-4) | 0.46 [0.04, 5.09] | | < 1 | | 0% | 2 studies (2/-) | 73.5 % | some concern | not evaluable | moderate | non important | - |
